InMode (NASDAQ:INMD) Hits New 52-Week Low at $16.82

InMode Ltd. (NASDAQ:INMD - Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $16.82 and last traded at $17.04, with a volume of 220546 shares trading hands. The stock had previously closed at $17.36.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Barclays cut their price target on shares of InMode from $34.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, April 12th. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a report on Tuesday, April 9th. Finally, UBS Group increased their target price on shares of InMode from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, February 14th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $32.80.

InMode Stock Down 2.0 %

The company's fifty day simple moving average is $20.43 and its 200 day simple moving average is $21.66. The firm has a market capitalization of $1.43 billion, a PE ratio of 7.40 and a beta of 2.16.

InMode (NASDAQ:INMD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.66 by $0.05. InMode had a net margin of 40.22% and a return on equity of 29.80%. The business had revenue of $126.80 million during the quarter, compared to analyst estimates of $124.77 million. During the same period last year, the business posted $0.69 earnings per share. InMode's quarterly revenue was down 5.1% compared to the same quarter last year. Equities research analysts forecast that InMode Ltd. will post 2.04 EPS for the current year.

Institutional Trading of InMode

Institutional investors and hedge funds have recently bought and sold shares of the stock. Meitav Investment House Ltd. increased its stake in shares of InMode by 22.1% during the fourth quarter. Meitav Investment House Ltd. now owns 1,940,890 shares of the healthcare company's stock valued at $43,166,000 after purchasing an additional 351,863 shares in the last quarter. LSV Asset Management increased its stake in shares of InMode by 15.6% during the fourth quarter. LSV Asset Management now owns 1,940,071 shares of the healthcare company's stock valued at $43,147,000 after purchasing an additional 261,252 shares in the last quarter. Boston Trust Walden Corp bought a new position in shares of InMode during the fourth quarter valued at approximately $32,366,000. DDD Partners LLC increased its stake in shares of InMode by 24.4% during the fourth quarter. DDD Partners LLC now owns 1,228,162 shares of the healthcare company's stock valued at $27,314,000 after purchasing an additional 240,856 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd increased its stake in shares of InMode by 44.0% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,080,000 shares of the healthcare company's stock valued at $32,897,000 after purchasing an additional 330,000 shares in the last quarter. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.